These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9815618)

  • 1. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
    Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
    Williams MD; Rostovtsev A; Narla RK; Uckun FM
    Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
    Hall PD; Kreitman RJ; Willingham MC; Frankel AE
    Toxicol Appl Pharmacol; 1998 May; 150(1):91-7. PubMed ID: 9630457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
    Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
    Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
    Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
    Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
    Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
    Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias.
    Perentesis JP; Bendel AE; Shao Y; Warman B; Davies SM; Yang CH; Chandan-Langlie M; Waddick KG; Uckun FM
    Leuk Lymphoma; 1997 Apr; 25(3-4):247-56. PubMed ID: 9168435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
    Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
    Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
    Hall PD; Willingham MC; Kreitman RJ; Frankel AE
    Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
    Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
    Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
    Hogge DE; Feuring-Buske M; Gerhard B; Frankel AE
    Leuk Res; 2004 Nov; 28(11):1221-6. PubMed ID: 15380349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
    Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
    Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of 131I-labeled granulocyte macrophage colony-stimulating factor in SCID mouse-acute myeloid leukemia model].
    Deng YJ; Lou SF; Xu YZ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):33-6. PubMed ID: 17649724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein.
    Hall PD; Beagle KL; Garrett-Mayer E; Frankel AE
    Anticancer Drugs; 2008 Nov; 19(10):1007-11. PubMed ID: 18827566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.
    Terpstra W; Rozemuller H; Breems DA; Rombouts EJ; Prins A; FitzGerald DJ; Kreitman RJ; Wielenga JJ; Ploemacher RE; Löwenberg B; Hagenbeek A; Martens AC
    Blood; 1997 Nov; 90(9):3735-42. PubMed ID: 9345060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
    Feuring-Buske M; Frankel A; Gerhard B; Hogge D
    Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein.
    Hogge DE; Willman CL; Kreitman RJ; Berger M; Hall PD; Kopecky KJ; McLain C; Tagge EP; Eaves CJ; Frankel AE
    Blood; 1998 Jul; 92(2):589-95. PubMed ID: 9657759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.